Hans Furuland

An exploration of markers of microvascular dysfunction in kidney transplant recipients randomized to belatacept: no clinical impact of CNIs on endothelial function

Bredewold, Edwin O. W.; Postma, Rudmer J.; Chan, Joe; Svensson, My H. S. et al.

Part of FRONTIERS IN TRANSPLANTATION, 2026

• DOI for An exploration of markers of microvascular dysfunction in kidney transplant recipients randomized to belatacept: no clinical impact of CNIs on endothelial function
• Download full text (pdf) of An exploration of markers of microvascular dysfunction in kidney transplant recipients randomized to belatacept: no clinical impact of CNIs on endothelial function

Potassium binders and continuation of renin-angiotensin system inhibitors/mineralocorticoid receptor antagonist in chronic kidney disease and heart failure (the DEMONSTRATE database)

Furuland, Hans; Larsson, Anders Olof; Uhde, Milica; Parv, Kristel et al.

Part of Journal of Internal Medicine, p. 179-192, 2026

• DOI for Potassium binders and continuation of renin-angiotensin system inhibitors/mineralocorticoid receptor antagonist in chronic kidney disease and heart failure (the DEMONSTRATE database)
• Download full text (pdf) of Potassium binders and continuation of renin-angiotensin system inhibitors/mineralocorticoid receptor antagonist in chronic kidney disease and heart failure (the DEMONSTRATE database)

Brain natriuretic peptide and all-cause mortality in patients treated with haemodialysis

Svensson, Maria K.; Nassar, Rita; Melin, Jan; Lindberg, Magnus et al.

Part of BMC Nephrology, 2025

• DOI for Brain natriuretic peptide and all-cause mortality in patients treated with haemodialysis
• Download full text (pdf) of Brain natriuretic peptide and all-cause mortality in patients treated with haemodialysis

Potassium binders in clinical practice: understanding potassium binder use in contemporary Swedish healthcare-the DEMONSTRATE database.

Furuland, Hans; Larsson, Anders Olof; Bjellerup, Per; Uhde, Milica et al.

Part of BMC Nephrology, p. 213, 2025

• DOI for Potassium binders in clinical practice: understanding potassium binder use in contemporary Swedish healthcare-the DEMONSTRATE database.
• Download full text (pdf) of Potassium binders in clinical practice: understanding potassium binder use in contemporary Swedish healthcare-the DEMONSTRATE database.

Anaemia and quality of life in chronic kidney disease: a consensus document from the European Anaemia of CKD Alliance

Dasgupta, Indranil; Bagnis, Corinne Isnard; Floris, Matteo; Furuland, Hans et al.

Part of Clinical Kidney Journal, 2024

• DOI for Anaemia and quality of life in chronic kidney disease: a consensus document from the European Anaemia of CKD Alliance
• Download full text (pdf) of Anaemia and quality of life in chronic kidney disease: a consensus document from the European Anaemia of CKD Alliance

An exploration of markers of microvascular dysfunction in kidney transplant recipients randomized to belatacept: no clinical impact of CNIs on endothelial function

Bredewold, Edwin O. W.; Postma, Rudmer J.; Chan, Joe; Svensson, My H. S. et al.

Part of FRONTIERS IN TRANSPLANTATION, 2026

• DOI for An exploration of markers of microvascular dysfunction in kidney transplant recipients randomized to belatacept: no clinical impact of CNIs on endothelial function
• Download full text (pdf) of An exploration of markers of microvascular dysfunction in kidney transplant recipients randomized to belatacept: no clinical impact of CNIs on endothelial function

Potassium binders and continuation of renin-angiotensin system inhibitors/mineralocorticoid receptor antagonist in chronic kidney disease and heart failure (the DEMONSTRATE database)

Furuland, Hans; Larsson, Anders Olof; Uhde, Milica; Parv, Kristel et al.

Part of Journal of Internal Medicine, p. 179-192, 2026

• DOI for Potassium binders and continuation of renin-angiotensin system inhibitors/mineralocorticoid receptor antagonist in chronic kidney disease and heart failure (the DEMONSTRATE database)
• Download full text (pdf) of Potassium binders and continuation of renin-angiotensin system inhibitors/mineralocorticoid receptor antagonist in chronic kidney disease and heart failure (the DEMONSTRATE database)

Brain natriuretic peptide and all-cause mortality in patients treated with haemodialysis

Svensson, Maria K.; Nassar, Rita; Melin, Jan; Lindberg, Magnus et al.

Part of BMC Nephrology, 2025

• DOI for Brain natriuretic peptide and all-cause mortality in patients treated with haemodialysis
• Download full text (pdf) of Brain natriuretic peptide and all-cause mortality in patients treated with haemodialysis

Potassium binders in clinical practice: understanding potassium binder use in contemporary Swedish healthcare-the DEMONSTRATE database.

Furuland, Hans; Larsson, Anders Olof; Bjellerup, Per; Uhde, Milica et al.

Part of BMC Nephrology, p. 213, 2025

• DOI for Potassium binders in clinical practice: understanding potassium binder use in contemporary Swedish healthcare-the DEMONSTRATE database.
• Download full text (pdf) of Potassium binders in clinical practice: understanding potassium binder use in contemporary Swedish healthcare-the DEMONSTRATE database.

Anaemia and quality of life in chronic kidney disease: a consensus document from the European Anaemia of CKD Alliance

Dasgupta, Indranil; Bagnis, Corinne Isnard; Floris, Matteo; Furuland, Hans et al.

Part of Clinical Kidney Journal, 2024

• DOI for Anaemia and quality of life in chronic kidney disease: a consensus document from the European Anaemia of CKD Alliance
• Download full text (pdf) of Anaemia and quality of life in chronic kidney disease: a consensus document from the European Anaemia of CKD Alliance

A case of enamel renal syndrome from a novel genetic mutation, multidisciplinary management and long-term prognosis

Erkapers, Maria; Frykholm, Carina; Furuland, Hans; Segerstrom, Susanna et al.

Part of Upsala Journal of Medical Sciences, 2024

• DOI for A case of enamel renal syndrome from a novel genetic mutation, multidisciplinary management and long-term prognosis
• Download full text (pdf) of A case of enamel renal syndrome from a novel genetic mutation, multidisciplinary management and long-term prognosis

Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: A Randomized Clinical Trial

Bredewold, Obbo W; Chan, Joe; Svensson, My; Bruchfeld, Annette et al.

Part of Kidney Medicine, 2023

• DOI for Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: A Randomized Clinical Trial
• Download full text (pdf) of Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: A Randomized Clinical Trial

Cost effectiveness of sodium zirconium cyclosilicate for the treatment of hyperkalaemia in patients with CKD in Norway and Sweden

Kim, Kun; Fagerström, Josefine; Chen, Gengshi; Lagunova, Zoya et al.

Part of BMC Nephrology, 2022

• DOI for Cost effectiveness of sodium zirconium cyclosilicate for the treatment of hyperkalaemia in patients with CKD in Norway and Sweden
• Download full text (pdf) of Cost effectiveness of sodium zirconium cyclosilicate for the treatment of hyperkalaemia in patients with CKD in Norway and Sweden

Effect of spironolactone on vascular stiffness in hemodialysis patients: a randomized crossover trial

Eklund, Michael; Hellberg, Olof; Furuland, Hans; Cao, Yang et al.

Part of Upsala Journal of Medical Sciences, 2022

• DOI for Effect of spironolactone on vascular stiffness in hemodialysis patients: a randomized crossover trial
• Download full text (pdf) of Effect of spironolactone on vascular stiffness in hemodialysis patients: a randomized crossover trial

Effects of spironolactone on extrasystoles and heart rate variability in haemodialysis patients: a randomised crossover trial

Eklund, Michael; Hellberg, Olof; Furuland, Hans; Cao, Yang et al.

Part of Upsala Journal of Medical Sciences, 2021

• DOI for Effects of spironolactone on extrasystoles and heart rate variability in haemodialysis patients: a randomised crossover trial
• Download full text (pdf) of Effects of spironolactone on extrasystoles and heart rate variability in haemodialysis patients: a randomised crossover trial

The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics

Wheeler, David C.; Stefansson, Bergur; Batiushin, Mikhail; Bilchenko, Oleksandr et al.

Part of Nephrology, Dialysis and Transplantation, p. 1700-1711, 2020

• DOI for The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics

Systematic fluid assessment in haemodialysis: Development and validation of a decision aid

Stenberg, Jenny; Keane, David; Lindberg, Magnus; Furuland, Hans

Part of Journal of Renal Care, p. 52-61, 2020

• DOI for Systematic fluid assessment in haemodialysis: Development and validation of a decision aid
• Download full text (pdf) of Systematic fluid assessment in haemodialysis: Development and validation of a decision aid

Implementation of a decision aid for recognition and correction of volume alterations (Recova^®) in haemodialysis patients

Stenberg, Jenny; Lindberg, Magnus; Furuland, Hans

Part of Upsala Journal of Medical Sciences, p. 281-292, 2020

• DOI for Implementation of a decision aid for recognition and correction of volume alterations (Recova^®) in haemodialysis patients
• Download full text (pdf) of Implementation of a decision aid for recognition and correction of volume alterations (Recova^®) in haemodialysis patients

Treatment of iron deficiency in patients with chronic kidney disease: A prospective observational study of iron isomaltoside (NIMO Scandinavia)

Jensen, Gert; Göransson, Lasse G.; Femström, Anders; Furuland, Hans et al.

Part of Clinical Nephrology, p. 246-253, 2019

• DOI for Treatment of iron deficiency in patients with chronic kidney disease: A prospective observational study of iron isomaltoside (NIMO Scandinavia)

Brain natriuretic peptide reflects individual variation in hydration status in hemodialysis patients

Stenberg, Jenny; Melin, Jan; Lindberg, Magnus; Furuland, Hans

Part of Hemodialysis International, p. 402-413, 2019

• DOI for Brain natriuretic peptide reflects individual variation in hydration status in hemodialysis patients
• Download full text (pdf) of Brain natriuretic peptide reflects individual variation in hydration status in hemodialysis patients

The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease

Evans, Marc; Palaka, Eirini; Furuland, Hans; Bennett, Hayley et al.

Part of BMC Nephrology, 2019

• DOI for The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease
• Download full text (pdf) of The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease

Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UK

Linde, Cecilia; Qin, Lei; Bakhai, Ameet; Furuland, Hans et al.

Part of ESC Heart Failure, p. 280-290, 2019

• DOI for Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UK
• Download full text (pdf) of Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UK

Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom

Linde, Cecilia; Bakhai, Ameet; Furuland, Hans; Evans, Marc et al.

Part of Journal of the American Heart Association, 2019

• DOI for Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom
• Download full text (pdf) of Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom

Perspectives on clinical use of bioimpedance in hemodialysis: focus group interviews with renal care professionals

Stenberg, Jenny; Henriksson, Catrin; Lindberg, Magnus; Furuland, Hans

Part of BMC Nephrology, 2018

• DOI for Perspectives on clinical use of bioimpedance in hemodialysis: focus group interviews with renal care professionals
• Download full text (pdf) of Perspectives on clinical use of bioimpedance in hemodialysis: focus group interviews with renal care professionals

RECURRENT HYPERKALAEMIA AND ASSOCIATION WITH LENGTH-OF-STAY AND MORTALITY FOLLOWING HOSPITALISATION: REAL-WORLD EVIDENCE FROM UK PATIENTS WITH CKD

Furuland, Hans; McEwan, Phil; Evans, Marc; Linde, Cecilia et al.

Part of Nephrology, Dialysis and Transplantation, p. 157-157, 2018

• DOI for RECURRENT HYPERKALAEMIA AND ASSOCIATION WITH LENGTH-OF-STAY AND MORTALITY FOLLOWING HOSPITALISATION: REAL-WORLD EVIDENCE FROM UK PATIENTS WITH CKD

RELATIONSHIP BETWEEN HYPERKALAEMIA AND DOWN-TITRATION OR DISCONTINUATION OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS IN UK PATIENTS WITH CKD

Linde, Cecilia; McEwan, Phil; Bakhai, Ameet; Furuland, Hans et al.

Part of Nephrology, Dialysis and Transplantation, p. 145-145, 2018

• DOI for RELATIONSHIP BETWEEN HYPERKALAEMIA AND DOWN-TITRATION OR DISCONTINUATION OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS IN UK PATIENTS WITH CKD

Serum potassium as a predictor of adverse clinical outcomes in patients with chronic kidney disease: new risk equations using the UK clinical practice research datalink

Furuland, Hans; McEwan, Phil; Evans, Marc; Linde, Cecilia et al.

Part of BMC Nephrology, 2018

• DOI for Serum potassium as a predictor of adverse clinical outcomes in patients with chronic kidney disease: new risk equations using the UK clinical practice research datalink
• Download full text (pdf) of Serum potassium as a predictor of adverse clinical outcomes in patients with chronic kidney disease: new risk equations using the UK clinical practice research datalink

Development of a health economic model to evaluate the potential benefits of optimal serum potassium management in patients with heart failure.

Bakhai, Ameet; Palaka, Eirini; Linde, Cecilia; Bennett, Hayley et al.

Part of Journal of Medical Economics, p. 1172-1182, 2018

• DOI for Development of a health economic model to evaluate the potential benefits of optimal serum potassium management in patients with heart failure.

Clinical praxis for assessment of dry weight in Sweden and Denmark: A mixed-methods study

Stenberg, Jenny; Lindberg, Magnus; Furuland, Hans

Part of Hemodialysis International, p. 111-119, 2016

• DOI for Clinical praxis for assessment of dry weight in Sweden and Denmark: A mixed-methods study
• Download full text (pdf) of Clinical praxis for assessment of dry weight in Sweden and Denmark: A mixed-methods study

Heart rate variability is decreased in chronic kidney disease but may improve with hemoglobin normalization

Furuland, Hans; Linde, Torbjörn; Englund, Anders; Wikström, Björn

Part of JN. Journal of Nephrology (Milano. 1992), p. 45-52, 2008

Hemorheological and hemodynamic changes in predialysis patients after normalization of hemoglobin with epoetin-alpha

Furuland, Hans; Linde, Torbjörn; Sandhagen, Bo; Andrén, Bertil et al.

Part of Scandinavian Journal of Urology and Nephrology, p. 399-404, 2005

• DOI for Hemorheological and hemodynamic changes in predialysis patients after normalization of hemoglobin with epoetin-alpha

Effect of switching from subcutaneous to intravenous administration of epoetin-alpha in haemodialysis patients: Results from a Swedish multicentre survey

Linde, Torbjörn; Furuland, Hans; Wikström, Björn

Part of Scandinavian Journal of Urology and Nephrology, p. 329-333, 2005

• DOI for Effect of switching from subcutaneous to intravenous administration of epoetin-alpha in haemodialysis patients: Results from a Swedish multicentre survey

Reduced hemodialysis adequacy after hemoglobin normalization with epoetin

Furuland, Hans; Linde, Torbjörn; Wikström, Björn; Danielson, Bo G.

Part of JN. Journal of Nephrology (Milano. 1992), p. 80-85, 2005

A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients

Furuland, Hans; Linde, Torbjörn; Ahlmén, Jarl; Christensson, Anders et al.

Part of Nephrology, Dialysis and Transplantation, p. 353-361, 2003

• DOI for A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients

Implementation of a Decision Aid for Recognition and Correction ofVolume Alterations (Recova®) in Hemodialysis

Stenberg, Jenny; Lindberg, Magnus; Furuland, Hans

p. 24-24, 2020

Systematic fluid assessment in haemodialysis care: Development and validation of adecision aid

Stenberg, Jenny; Keane, David; Lindberg, Magnus; Furuland, Hans

p. 85-85, 2019

Bedside BNP as a marker of overhydration in hemodialysis patients

Melin, Jan; Stenberg, Jenny; Lindberg, Magnus; Furuland, Hans

p. 878-878, 2017

Clinical praxis for assessment of dry weight in Sweden and Denmark: a mixed-methods study

Stenberg, Jenny; Lindberg, Magnus; Furuland, Hans

p. 108-108, 2015